Meet with Cancer Genetics at ASH

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
November 29th, 2016

Anna Israyelyan, MD, PhD

Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.


At the world’s premier event in hematology, the American Society of Hematology (ASH) Annual Meeting will provide it’s over 20,000 attendees with an opportunity to explore the year’s most significant research and discoveries in the field.  It’s also a time to connect with old friends, meet new ones, and learn about the latest industry trends. With strong research collaborations, an extensive track record in innovative assay development, as well as our expertise in diagnosis, prognosis, and theranosis of heme malignancies, Cancer Genetics, Inc. (CGI) is slated for multiple presentations at ASH this year, including updates from collaborations with Keck School of Medicine of University of Southern California and Weill Cornell Medical College. In addition, CGI will exhibit the wide range of its products and services along with about 250 companies in the Exhibit Hall at Booth 4543.

CGI’s Comprehensive and Clinically Actionable Focus::Lymphoma™ Panel Utilized to Shed Light onto Biomarkers in  DLBCL

CGI’s proprietary next generation sequencing (NGS) panel, Focus::Lymphoma™, with 220 genes most commonly mutated in B-cell non-Hodgkin Lymphoma (NHL) was utilized in a study with Keck School of Medicine of USC exploring rational and reliable biomarkers for selecting diffuse large B-cell lymphoma (DLBCL) patients to benefit from checkpoint inhibitor therapies.

Please attend the podium presentation PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and is Associated with Several Genomic Markers” on Saturday, December 3, 12:30pm, in Room 31.   

Additional Insight into DLBCL in Concert with Weill Cornell

Previous work has established  inferior outcome in DLBCL is associated with higher degrees of intra-tumor and inter-tumor cytosine methylation heterogeneity, although the molecules driving this epigenetic perturbation remain unknown. The study with Weill Cornell Medical College investigated the contribution of activation-induced cytidine deaminase (AICDA) to cytosine methylation heterogeneity in DLBCLs.

Please attend the podium presentation “AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis” on Monday, December 5, 4:30pm, in Room 31.

CGI Experts at ASH

rita-2 tu-2 narasimha-2

Rita Shaknovich, MD, PhD 
Group Medical Director and VP of  Hematopathology, CGI

TuDung Nguyen, MD, PhD
Medical Director, CGI

Narasimha Marella, PhD
VP of Operations, CGI
kamala-2 leslie-2

Kamala Maddali, DVM, PhD
VP, Biopharm Collaborations & Companion Diagnostics, CGI

Leslie Abad, MS
Sr Director of Biopharm Marketing & Collaborations, CGI

 

CGI Collaborators at ASH

imran-2 ari-2

Imran Siddiqi, MD, PhD
Assistant Professor of Clinical Pathology, Keck School of Medicine of USC

Ari Melnick, MD
Professor of Hematology/Oncology, Weill Cornell Medical College

 

Please reach out to me to schedule individual meetings with any of our experts:

Anna Israyelyan, MD, PhD
Clinical Affairs Manager
Anna.Israyelyan@cgix.com
Tel: 323.224.3900 x175

You can also connect with me on LinkedIn.

Comments

comments